Management of bisphosphonate-induced osteonecrosis of the jaw.
In conclusion, careful treatment planning minimizes BIONJ risk in patients with bisphosphonate exposure. The drug type, dose, potency, and duration are important factors in determining the cumulative effect on bone remodeling and resultant risk of BIONJ. Dentists and physicians should work closely to balance the risks of the oral and systemic conditions surrounding bisphosphonate use. A critical assessment of current literature is necessary to best serve our patients.
Schilling
Jody
J
University of Minnesota, School of Dentistry, Department of Periodontology, Minneapolis, Minnesota, USA.
D000284:Administration, Oral; D000368:Aged; D015415:Biomarkers / Q000097:blood; D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000009:adverse effects*; D024042:Collagen Type I / Q000097:blood; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007571:Jaw Diseases / Q000139:chemically induced / Q000517:prevention & control / Q000628:therapy*; D010020:Osteonecrosis / Q000139:chemically induced / Q000517:prevention & control / Q000628:therapy*; D010455:Peptides / Q000097:blood; D018570:Risk Assessment
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D004164:Diphosphonates; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide